Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development ...

Topline results expected to be released in August 2025Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc.

CMND-100 is Clearmind’s proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel ...

Detailed price information for Spectral Medical Inc (EDT-T) from The Globe and Mail including charting and trades.

This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company ... is a significant step in our journey toward FDA ...

This follows the March 27 announcement of the product launch and represents a key milestone ... (FDA) has designated YUFLYMA® (adalimumab-aaty), as an interchangeable biosimilar to Humira® (adalimumab ...

Evan Vucci/AP According to Rasmussen's daily poll tracker, as of April 4, Trump's approval rating sits at 49 percent, while 50 percent disapprove of his job performance. That is the first time in ...

Argent BioPharma (ASX:RGT) said the approval marked a major milestone in the company’s European expansion strategy and reinforced its commitment to providing innovative treatments for central ...

Followed categories will be added to My News. Argent BioPharma (ASX:RGT) said the approval marked a major milestone in the company’s European expansion strategy and reinforced its commitment to ...